GlassScriptPhysician profile
Tomoki Sempokuya
NPI 1013370725
$5,453.94
in general payments reported to CMS, 2019-2025
23 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,061 · 2024: $2,856 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,695.20 | 2023-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $635.39 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbvie INC. | $499.98 | 2023-2025 | Mavyret |
| Ipsen Biopharmaceuticals, INC | $479.91 | 2024-2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $288.41 | 2024-2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $249.69 | 2023-2025 | Ocaliva |
| Fujifilm Healthcare Americas Corporation | $204.55 | 2024 | Utaswako Afp-L3 |
| Orphalan INC | $177.95 | 2024 | Cuvrior |
| Mallinckrodt Hospital Products INC. | $170.37 | 2024-2025 | Terlivaz |
| Boston Scientific Corporation | $169.58 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Histosonics, INC. | $141.47 | 2024 | |
| Baxter Healthcare | $121.60 | 2024 | Renal - Acute |
| Exelixis INC. | $118.98 | 2023 | Cabometyx |
| Exact Sciences Corporation | $106.72 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.12 | 2023-2025 | Entyvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $65.94 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $63.92 | 2023-2025 | Imfinzi |
| Genzyme Corporation | $45.25 | 2025 | |
| Celgene Corporation | $39.75 | 2024 | Zeposia |
| Lilly USA, LLC | $33.40 | 2024 | Omvoh |
| Genentech, INC. | $31.11 | 2023 | Avastin, Tecentriq |
| Echosens North America, INC. | $22.33 | 2024 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.32 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomoki Sempokuya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.